Skip to main content
Registrieren
Springer Medizin
SUCHE
MENÜ 1 2 3 4
main-content
nach oben
Erschienen in: Im Fokus Onkologie 3/2014

29.03.2014 | Zertifizierte Fortbildung

Hochpräzisionsbestrahlung bei Lungentumoren

Radiochirurgie in der Onkologie

verfasst von: Dr. med. Thomas Schneider, PD Dr. med. Fabian Fehlauer, Prof. Dr. med. Michael Heinrich Seegenschmiedt, Karen Piefel, Simone Glessmer-Junike

Erschienen in: Im Fokus Onkologie | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Zusammenfassung

Durch technische Weiterentwicklungen haben die Möglichkeiten der Radiotherapie zugenommen. So können nun auch atembewegliche Zielvolumina sehr genau bestrahlt werden. Dabei kommt die sogenannte stereotaktische Radiotherapie sowohl bei primären Lungentumoren als auch bei Lungenmetastasen zum Einsatz.
Literatur
1.
Li J et al. Dosimetric verification using monte carlo calculations for tissue heterogeneity-corrected conformal treatment plans following RTOG 0813 dosimetric criteria for lung cancer stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys. 2012;84(2):508–513. PubMedCentralPubMedCrossRef
2.
RTOG 0915 Protocol Information: A Randomized Phase II Study Comparing 2 Stereotactic Body Radiation Therapy (SBRT) Schedules for Medically Inoperable Patients with Stage I Peripheral Non-Small Cell Lung Cancer (http://​www.​rtog.​org/​ClinicalTrials/​ProtocolTable/​StudyDetails.​aspx?​study=​0915).
3.
DIN 6847-5, 6858-1, 6870-1, 6873-5,6875-1, 6875-2.
4.
Keall PJ et al. The management of respiratory motion in radiation oncology report of AAPM Task Group 76. Med Phys. 2006;33(10):3874–3900. PubMedCrossRef
5.
6.
Wong JW et al. The use of active breathing control (ABC) to reduce margin for breathing motion. Int J Radiat Oncol Biol Phys. 1999;44(4):911–919. PubMedCrossRef
7.
Negoro Y et al. The effectiveness of an immobilization device in conformal radiotherapy for lung tumor: reduction of respiratory tumor movement and evaluation of the daily setup accuracy. Int J Radiat Oncol Biol Phys. 2001;50(4):889–898. PubMedCrossRef
8.
Blomgren H et al. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. Acta Oncol. 1995;34(6):861–870. PubMedCrossRef
9.
Hamilton AJ, Lulu BA. A prototype device for linear accelerator-based extracranial radiosurgery. Acta Neurochir Suppl. 1995;63:40–43. PubMed
10.
Uematsu M et al. Focal, high dose, and fractionated modified stereotactic radiation therapy for lung carcinoma patients: a preliminary experience. Cancer. 1998;82(6):1062–1070. PubMedCrossRef
11.
Wulf J et al. Stereotactic radiotherapy for primary lung cancer and pulmonary metastases: a noninvasive treatment approach in medically inoperable patients. Int J Radiat Oncol Biol Phys. 2004;60(1):186–196. PubMedCrossRef
12.
Renaud S et al. Is radiofrequency ablation or stereotactic ablative radiotherapy the best treatment for radically treatable primary lung cancer unfit for surgery? Interact Cardiovasc Thorac Surg. 2013;16(1):68–73. PubMedCentralPubMedCrossRef
13.
14.
Onishi H et al. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer. 2004;101(7):1623–1631. PubMedCrossRef
15.
Soldà F et al. Stereotactic radiotherapy (SABR) for the treatment of primary non-small cell lung cancer; systematic review and comparison with a surgical cohort. Radiother Oncol. 2013;109(1):1–7. PubMedCrossRef
16.
Nagata Y et al. Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys. 2005;63(5):1427–1431. PubMedCrossRef
17.
Baumann P et al. Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol. 2009;27(20):3290–3296. PubMedCrossRef
18.
Fakiris AJ et al. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys. 2009;75(3):677–682. PubMedCrossRef
19.
Ricardi U et al. Stereotactic body radiation therapy for early stage nonsmall cell lung cancer: results of a prospective trial. Lung Cancer. 2010;68(1):72–77. PubMedCrossRef
20.
Baba F et al. Clinical outcomes of stereotactic body radiotherapy for stage I non-small cell lung cancer using different doses depending on tumor size. Radiat Oncol. 2010;5:81. PubMedCentralPubMedCrossRef
21.
22.
Haasbeek CJ et al. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. J Thorac Oncol. 2011;6(12):2036–2043. PubMedCrossRef
23.
Bral S et al. Prospective, risk-adapted strategy of stereotactic body radiotherapy for early-stage non-small-cell lung cancer: results of a Phase II trial. Int J Radiat Oncol Biol Phys. 2011;80(5):1343–1349. PubMedCrossRef
24.
Rowe BP et al. Stereotactic body radiotherapy for central lung tumors. J Thorac Oncol. 2012;7(9):1394–1399. PubMedCrossRef
25.
Janssen S et al. Image-guided hypofractionated small volume radiotherapy of non-small cell lung cancer - feasibility and clinical outcome. Onkologie. 2012;35(7-8):408–412. PubMedCrossRef
26.
Wulf J et al. Stereotactic radiotherapy for primary lung cancer and pulmonary metastases: a noninvasive treatment approach in medically inoperable patients. Int J Radiat Oncol Biol Phys. 2004;60(1):186–196. PubMedCrossRef
27.
Zimmermann FB et al. Stereotactic hypofractionated radiotherapy in stage I (T1-2 N0 M0) non-small-cell lung cancer (NSCLC). Acta Oncol. 2006;45(7):796–801. PubMedCrossRef
28.
Hof H et al. Stereotactic single-dose radiotherapy of lung metastases. Strahlenther Onkol. 2007;183(12):673–678. PubMedCrossRef
29.
Andratschke N et al. Stereotactic radiotherapy of histologically proven inoperable stage I non-small cell lung cancer: patterns of failure. Radiother Oncol. 2011;101(2):245–249. PubMedCrossRef
30.
Guckenberger M et al. Safety and efficacy of stereotactic body radiotherapy for stage 1 non-small-cell lung cancer in routine clinical practice: a patterns-of-care and outcome analysis. J Thorac Oncol. 2013;8(8):1050–1058. PubMedCrossRef
31.
Timmerman R et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol. 2006;24(30):4833–4839. PubMedCrossRef
32.
Baumann P et al. Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries. Acta Oncol. 2006;45(7):787–795. PubMedCrossRef
33.
Song SY et al. Fractionated stereotactic body radiation therapy for medically inoperable stage I lung cancer adjacent to central large bronchus. Lung Cancer. 2009;66(1):89–93. PubMedCrossRef
34.
van der Voort van Zyp NC et al. Stereotactic radiotherapy with real-time tumor tracking for non-small cell lung cancer: clinical outcome. Radiother Oncol. 2009;91(3):296–300. PubMedCrossRef
35.
Nuyttens JJ et al. Outcome of four-dimensional stereotactic radiotherapy for centrally located lung tumors. Radiother Oncol. 2012;102(3):383–387. PubMedCrossRef
36.
Senthi S et al. Outcomes of stereotactic ablative radiotherapy for central lung tumours: a systematic review. Radiother Oncol. 2013;106(3):276–282. PubMedCrossRef
37.
Wu SX et al. [Therapeutic analysis of stereotactic radiotherapy for 39 patients with lung metastasis]. Ai Zheng. 2006;25(7):880–884. PubMed
38.
Okunieff P et al. Stereotactic Body Radiation Therapy (SBRT) for lung metastases. Acta Oncol. 2006;45(7):808–817. PubMedCrossRef
39.
Hof H et al. Stereotactic single-dose radiotherapy of lung metastases. Strahlenther Onkol. 2007;183(12):673–678. PubMedCrossRef
40.
Norihisa Y et al. Stereotactic body radiotherapy for oligometastatic lung tumors. Int J Radiat Oncol Biol Phys. 2008;72(2):398–403. PubMedCrossRef
41.
Guckenberger M et al. Dose-response relationship for image-guided stereotactic body radiotherapy of pulmonary tumors: relevance of 4D dose calculation. Int J Radiat Oncol Biol Phys. 2009;74(1):47–54. PubMedCrossRef
42.
Rusthoven KE et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol. 2009;27(10):1579–1584. PubMedCrossRef
43.
Masciullo 2010 Stereotactic body radiotherapy for oligometastatic non small cell lung cancer patients ASTRO 2010: Poster presentation
44.
Zhang Y et al. Stereotactic body radiation therapy favors long-term overall survival in patients with lung metastases: five-year experience of a single-institution. Chin Med J (Engl). 2011;124(24):4132–4137.
45.
Dhakal S et al. Stereotactic body radiotherapy for pulmonary metastases from soft-tissue sarcomas: excellent local lesion control and improved patient survival. Int J Radiat Oncol Biol Phys. 2012;82(2):940–945. PubMedCrossRef
46.
Baschnagel AM et al. Lung metastases treated with image-guided stereotactic body radiation therapy. Clin Oncol (R Coll Radiol). 2013;25(4):236–241. CrossRef
47.
48.
49.
Siva S et al. Stereotactic radiotherapy for pulmonary oligometastases: a systematic review. J Thorac Oncol. 2010;5(7):1091–1099. PubMed
50.
Blackstock AW, Govindan R. Definitive chemoradiation for the treatment of locally advanced non small-cell lung cancer. J Clin Oncol. 2007;25(26):4146–4152. PubMedCrossRef
51.
Gressen EL et al. Thoracic reirradiation for symptomatic relief after prior radiotherapeutic management for lung cancer. Am J Clin Oncol. 2000;23(2):160–163. PubMedCrossRef
52.
Green N, Melbye RW. Lung cancer: retreatment of local recurrence after definitive irradiation. Cancer. 1982;49(5):865–868. PubMedCrossRef
53.
Jackson MA, Ball DL. Palliative retreatment of locally-recurrent lung cancer after radical radiotherapy. Med J Aust. 1987;147(8):391–394. PubMed
54.
55.
Poltinnikov IM et al. Combination of longitudinal and circumferential three-dimensional esophageal dose distribution predicts acute esophagitis in hypofractionated reirradiation of patients with non-small-cell lung cancer treated in stereotactic body frame. Int J Radiat Oncol Biol Phys. 2005;62(3):652–658. PubMedCrossRef
56.
Coon D et al. Fractionated stereotactic body radiation therapy in the treatment of primary, recurrent, and metastatic lung tumors: the role of positron emission tomography/computed tomography-based treatment planning. Clin Lung Cancer. 2008;9(4):217–221. PubMedCrossRef
57.
Kelly P et al. Stereotactic body radiation therapy for patients with lung cancer previously treated with thoracic radiation. Int J Radiat Oncol Biol Phys. 2010;78(5):1387–1393. PubMedCentralPubMedCrossRef
58.
Peulen H et al. Toxicity after reirradiation of pulmonary tumours with stereotactic body radiotherapy. Radiother Oncol. 2011;101(2):260–266. PubMedCrossRef
59.
Grutters JP et al. Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: a meta-analysis. Radiother Oncol. 2010;95(1):32–40. PubMedCrossRef
Metadaten
Titel
Hochpräzisionsbestrahlung bei Lungentumoren
Radiochirurgie in der Onkologie
verfasst von
Dr. med. Thomas Schneider
PD Dr. med. Fabian Fehlauer
Prof. Dr. med. Michael Heinrich Seegenschmiedt
Karen Piefel
Simone Glessmer-Junike
Publikationsdatum
29.03.2014
Verlag
Urban & Vogel
Erschienen in
Im Fokus Onkologie / Ausgabe 3/2014
Print ISSN: 1435-7402
Elektronische ISSN: 2192-5674
DOI
https://doi.org/10.1007/s15015-014-0002-z

Weitere Artikel der Ausgabe 3/2014

Im Fokus Onkologie 3/2014 Zur Ausgabe

Literatur kompakt_Tumoren der Lunge

SCLC im Frühstadium: Vorteil durch alternativen Topoisomerasehemmer?

Literatur kompakt_Mammakarzinom

Chemotherapie bei Älteren mit Mammakarzinom

Literatur kompakt_ZNS-Tumoren

Dosisdichte Therapie lohnt sich nicht für Patienten mit Glioblastom

Literatur kompakt_ Kopf-Hals-Tumoren

Schilddrüsenkarzinom: länger progressionsfrei

Panorama

Top-Fortschritt 2013

Literatur kompakt_ Kopf-Hals-Tumoren

SCCHN: EGFR-Blockade plus Chemotherapie

Neu im Fachgebiet Onkologie

24.06.2022 | NSCLC | Nachrichten

EGFR-Status bei NSCLC auch in frühen Stadien hilfreich

22.06.2022 | Hauptstadtkongress 2022 | Nachrichten

Mehr als nur COVID-19-Impfstoffe: mRNA in der Medizin

22.06.2022 | Ovarialkarzinom | Nachrichten

Vier von fünf Frauen für Gabe von PARP-Hemmern geeignet?

22.06.2022 | Prostatakarzinom | Nachrichten

Aktive Überwachung mit Antiandrogen kombinieren?
weitere anzeigen

Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen
» zur Themenseite Onkologie rotated-square
Bildnachweise

Version: 0.2002.0